Clinical Trial

A Study of NTX-1472 in Social Anxiety Disorder

Study acronym: SOAR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-06; most recent amendment 2026-07-07.
Trial Details
NCT Number NCT07323784
Lead Sponsor Newleos Therapeutics, Inc.
Conditions Social Anxiety Disorder (SAD)
Enrollment 100 participants
Start Date 2025-12-09
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09